News ArchivesRead News
Michael J. Fox Foundation: New treatment for Parkinson's Disease
Tuesday April 24, 2012
Digital Journal - The Michael J. Fox Foundation, which was set up in the name of the actor to study Parkinson's Disease, has announced that it is to work with the ‘big pharma’ company Sanofi to look at a potential new treatment for the disease.
The Michael J. Fox Foundation and the company Sanofi have announced trials for a new treatment for Parkinson's Disease.
Parkinson’s Disease is a disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement, and coordination. The Michael J. Fox Foundation (MJFF) is a charitable organization is dedicated to finding a cure for Parkinson’s disease and the development of improved therapies for those living with Parkinson’s. The organization works with the actor, Michael J. Fox, who has Parkinson’s Disease. Fox first developed the disease in 1990.
The drug company Sanofi has entered into a collaboration the MJFF to conduct a clinical trial to assess the safety and tolerability of new drug, a type of inhibitor called phosphodiesterase (coded AVE8112), which is designed to help patients with Parkinson's Disease.
According to the Top News Net, Todd Sherer, Ph.D., Chief Executive Officer of MJFF, said that the drug had:
"Shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives. Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation's approach and help us speed scientific advances with potential to improve the treatment of Parkinson's for patients today and in the future."
Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson's disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi.
To add to this, the Euro Pharma Review quotes Dr. Elias Zerhouni, President, Global R&D, Sanofi, as saying “The Michael J. Fox Foundation has been a driving force in discovering and developing improved therapies for those living with Parkinson's disease. Through this research collaboration, together we will be able to study Sanofi's pharmaceutical compound for a possible new treatment for PD patients around the world.”
Further development plans will be based upon the results of the study.
Recent NewsAug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement
Jul 19 - What Young-onset Parkinson’s Can Look Like
Jul 7 - Parkinson’s Patients Have a Higher Risk of Developing Melanoma — and Vice Versa, Study Finds
Jun 27 - The rogue protein behind Parkinson’s disease may also protect your gut
Jun 26 - Do Statins Increase Risk of Parkinson’s Disease? Some Researchers Think So
Jun 22 - A Confused Immune System Could Be Behind Parkinson's Disease
Jun 21 - Predicting cognitive deficits in people with Parkinson’s disease
Jun 20 - Gym offers classes in noncontact boxing for Parkinson’s patients
Jun 19 - Human Limitations Could Prevent Us From Advancing in Science. AI Could Help.
Jun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease